Go Pro
→ These 3 Stocks Could Soar as Sam Altman Announces New Venture After OpenAI (From Stansberry Research) (Ad)tc pixel Free BTTX Stock Alerts

Better Therapeutics (BTTX) Competitors

Better Therapeutics logo
$0.0001 0.00 (0.00%)
As of 02:51 PM Eastern
Compare

BTTX vs. UPHL, VRAYQ, IMAC, NAVB, and WINT

Should you buy Better Therapeutics stock or one of its competitors? Better Therapeutics's main competitors and comparable companies include UpHealth (UPHL), ViewRay (VRAYQ), IMAC (IMAC), Navidea Biopharmaceuticals (NAVB), and Windtree Therapeutics (WINT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Better Therapeutics compare to UpHealth?

UpHealth (NYSE:UPHL) and Better Therapeutics (NASDAQ:BTTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

56.1% of UpHealth shares are owned by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are owned by institutional investors. 34.2% of UpHealth shares are owned by insiders. Comparatively, 51.4% of Better Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, UpHealth had 1 more articles in the media than Better Therapeutics. MarketBeat recorded 1 mentions for UpHealth and 0 mentions for Better Therapeutics. Better Therapeutics' average media sentiment score of 0.00 beat UpHealth's score of -0.71 indicating that Better Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
UpHealth Negative
Better Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
UpHealthN/A N/A N/A
Better Therapeutics N/A N/A N/A

UpHealth has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market. Comparatively, Better Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Better Therapeutics has lower revenue, but higher earnings than UpHealth. Better Therapeutics is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UpHealth$130M0.00-$56.42M$1.980.00
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A

Summary

UpHealth beats Better Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Better Therapeutics compare to ViewRay?

Better Therapeutics (NASDAQ:BTTX) and ViewRay (NASDAQ:VRAYQ) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of ViewRay shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by insiders. Comparatively, 2.5% of ViewRay shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled ViewRay'saverage media sentiment score.

Company Overall Sentiment
Better Therapeutics Neutral
ViewRay Neutral

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
ViewRay N/A N/A N/A

Better Therapeutics has higher earnings, but lower revenue than ViewRay.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A
ViewRay$102.21M0.00-$107.33MN/AN/A

Better Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, ViewRay has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Summary

Better Therapeutics beats ViewRay on 5 of the 6 factors compared between the two stocks.

How does Better Therapeutics compare to IMAC?

Better Therapeutics (NASDAQ:BTTX) and IMAC (NASDAQ:IMAC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

34.0% of Better Therapeutics shares are held by institutional investors. Comparatively, 24.3% of IMAC shares are held by institutional investors. 51.4% of Better Therapeutics shares are held by insiders. Comparatively, 10.0% of IMAC shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, IMAC had 2 more articles in the media than Better Therapeutics. MarketBeat recorded 2 mentions for IMAC and 0 mentions for Better Therapeutics. IMAC's average media sentiment score of 0.14 beat Better Therapeutics' score of 0.00 indicating that IMAC is being referred to more favorably in the news media.

Company Overall Sentiment
Better Therapeutics Neutral
IMAC Neutral

Better Therapeutics has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, IMAC has a beta of -0.88, indicating that its share price is 188% less volatile than the broader market.

Better Therapeutics has a net margin of 0.00% compared to IMAC's net margin of -75.40%. Better Therapeutics' return on equity of 0.00% beat IMAC's return on equity.

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
IMAC -75.40%-52.17%-34.51%

IMAC has higher revenue and earnings than Better Therapeutics. IMAC is trading at a lower price-to-earnings ratio than Better Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A
IMAC$15.22M0.00-$10.54M-$0.27N/A

Summary

Better Therapeutics beats IMAC on 7 of the 12 factors compared between the two stocks.

How does Better Therapeutics compare to Navidea Biopharmaceuticals?

Better Therapeutics (NASDAQ:BTTX) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Navidea Biopharmaceuticals has higher revenue and earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Better Therapeutics Neutral
Navidea Biopharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Better Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

34.0% of Better Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 51.4% of Better Therapeutics shares are owned by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Navidea Biopharmaceuticals beats Better Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Better Therapeutics compare to Windtree Therapeutics?

Better Therapeutics (NASDAQ:BTTX) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

34.0% of Better Therapeutics shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 51.4% of Better Therapeutics shares are held by company insiders. Comparatively, 0.2% of Windtree Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Better Therapeutics' average media sentiment score of 0.00 equaled Windtree Therapeutics'average media sentiment score.

Company Overall Sentiment
Better Therapeutics Neutral
Windtree Therapeutics Neutral

Better Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.39N/A
Windtree TherapeuticsN/AN/A-$1.79M-$8.77N/A

Better Therapeutics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.64, meaning that its share price is 64% more volatile than the broader market.

Better Therapeutics' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
Windtree Therapeutics N/A -207.34%-50.19%

Summary

Better Therapeutics beats Windtree Therapeutics on 5 of the 8 factors compared between the two stocks.

Get Better Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BTTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BTTX vs. The Competition

Export
MetricBetter TherapeuticsHealth services IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4K$837.00K$7.37B$12.86B
Dividend YieldN/AN/A2.53%10.69%
P/E Ratio0.00N/A268.4324.05
Price / SalesN/A0.00621.4092.73
Price / CashN/AN/A78.1353.57
Price / BookN/A0.0013.076.15
Net Income-$39.76M-$48.09M$3.46B$347.39M
7 Day PerformanceN/AN/A1.43%-0.64%
1 Month PerformanceN/AN/A4.58%2.12%
1 Year PerformanceN/AN/A27.60%20.16%

Better Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BTTX
Better Therapeutics
N/A$0.00
flat		N/AN/A$4KN/AN/A40
UPHL
UpHealth
N/A$0.00
flat		N/A+50.0%$6K$130MN/A1,750
VRAYQ
ViewRay
N/AN/AN/AN/A$16K$102.21MN/A300
IMAC
IMAC
N/A$0.00
flat		N/AN/A$13K$15.22MN/A106
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BTTX) was last updated on 8/20/2026 by MarketBeat.com Staff.
From Our Partners
Do you own 100 shares of anything? Read this
Jerremy Newsome retired at 24 and has been a keynote speaker at The Money Show for more than a decade. His ...
Jerremy Newsome | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
Look at this $5 stock’s address
A small public company trading under $5 a share operates inside the secure perimeter of Kennedy Space Center, ...
Freedom Financial | Sponsoredtc pixel
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
One Ticker Tied to a Major White House Move You Should Know
Larry Benedict made 274 million dollars for his clients by spotting major market moves before they happened. ...
Brownstone Research | Sponsoredtc pixel